Synthesis of Fluorine-18 Functionalized Nanoparticles for use as in vivo Molecular Imaging Agents

2008 ◽  
Vol 130 (21) ◽  
pp. 6731-6733 ◽  
Author(s):  
John B. Matson ◽  
Robert H. Grubbs
Keyword(s):  
Molecular Imaging ◽  
Imaging Agents ◽  
Functionalized Nanoparticles ◽  
Molecular Imaging Agents

Development of new PTK7-targeting aptamer-fluorescent and -radiolabelled probes for evaluation as molecular imaging agents: Lymphoma and melanoma in vivo proof of concept

2017 ◽  
Vol 25 (3) ◽  
pp. 1163-1171 ◽  
Author(s):  
Victoria Calzada ◽  
María Moreno ◽  
Jessica Newton ◽  
Joel González ◽  
Marcelo Fernández ◽  
...  
Keyword(s):  
Molecular Imaging ◽  
Imaging Agents ◽  
Proof Of Concept ◽  
Molecular Imaging Agents

scholarly journals Fluorine-18 capture by substituted BODIPY derivatives

2015 ◽  
Author(s):  
◽  
Patrick L. Cavins
Keyword(s):  
Survival Rate ◽  
Molecular Imaging ◽  
Biological Molecules ◽  
Medical Community ◽  
Imaging Agents ◽  
New Class ◽  
Molecular Imaging Agents ◽  
Peptide Expression ◽  
Peptide Imaging

For the medical community to effectively decrease the number of deaths caused by cancer each year, we must develop tools that allow for the early detection of biological abnormalities. Earlier detection is key to increasing the survival rate among cancer patients. A major tool currently used by the medical community is molecular imaging. However, the scope of molecular imaging is limited, so new molecular imaging agents must be developed. One the most ubiquitous biological molecules are peptides, and changes in peptide expression has been associated with cancer. However, molecular imaging does not presently have the tools required to monitor the entire class of peptides. In order to increase the scope of molecular imaging in regard to peptides, we have endeavored to create a new class of peptide imaging agents based on the BODIPY fluorophore. To date, we have demonstrated the ability of this scaffold to work effectively as an imaging agent in mouse models. These dyes are lipophilic in vivo so newer generations of this scaffold will have to address these concerns.

Magnetic Resonance Contrast Media Sensing In Vivo Molecular Imaging Agents: An Overview

2011 ◽  
Vol 4 (1) ◽  
pp. 31-43 ◽  
Author(s):  
Massoud Amanlou ◽  
Seyed Davar Siadat ◽  
Dariush Norouzian ◽  
Seyed Esmaeil Sadat Ebrahimi ◽  
Mohammad Reza Aghasadeghi ◽  
...  
Keyword(s):  
Molecular Imaging ◽  
Magnetic Resonance ◽  
Contrast Media ◽  
Imaging Agents ◽  
Molecular Imaging Agents ◽  
Magnetic Resonance Contrast ◽  
Resonance Contrast

scholarly journals High-throughput in vivo screening of targeted molecular imaging agents

2009 ◽  
Vol 106 (42) ◽  
pp. 17904-17909 ◽  
Author(s):  
M. K. J. Gagnon ◽  
S. H. Hausner ◽  
J. Marik ◽  
C. K. Abbey ◽  
J. F. Marshall ◽  
...  
Keyword(s):  
Molecular Imaging ◽  
High Throughput ◽  
Imaging Agents ◽  
In Vivo Screening ◽  
Molecular Imaging Agents ◽  
Targeted Molecular Imaging

scholarly journals A Systematic Review of Molecular Imaging Agents Targeting Bradykinin B1 and B2 Receptors

2020 ◽  
Vol 13 (8) ◽  
pp. 199
Author(s):  
Joseph Lau ◽  
Julie Rousseau ◽  
Daniel Kwon ◽  
François Bénard ◽  
Kuo-Shyan Lin
Keyword(s):  
Molecular Imaging ◽  
Smooth Muscle Contraction ◽  
Therapeutic Interventions ◽  
Imaging Agents ◽  
Kinin System ◽  
Normal Tissues ◽  
Molecular Imaging Agents ◽  
Inflammatory State ◽  
B2 Receptors ◽  
Tissue Trauma

Kinins, bradykinin and kallidin are vasoactive peptides that signal through the bradykinin B1 and B2 receptors (B1R and B2R). B2R is constitutively expressed in healthy tissues and mediates responses such as vasodilation, fluid balance and retention, smooth muscle contraction, and algesia, while B1R is absent in normal tissues and is induced by tissue trauma or inflammation. B2R is activated by kinins, while B1R is activated by kinins that lack the C-terminal arginine residue. Perturbations of the kinin system have been implicated in inflammation, chronic pain, vasculopathy, neuropathy, obesity, diabetes, and cancer. In general, excess activation and signaling of the kinin system lead to a pro-inflammatory state. Depending on the disease context, agonism or antagonism of the bradykinin receptors have been considered as therapeutic options. In this review, we summarize molecular imaging agents targeting these G protein-coupled receptors, including optical and radioactive probes that have been used to interrogate B1R/B2R expression at the cellular and anatomical levels, respectively. Several of these preclinical agents, described herein, have the potential to guide therapeutic interventions for these receptors.

Sign in / Sign up

Export Citation Format

Share Document